Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom

Objectives We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) receiving recombinant von Willebrand factor (rVWF) in surgical settings in the United Kingdom. Methods Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the prevention/treatment of surgery‐related bleeds, or the on‐demand treatment of spontaneous/traumatic bleeds, between 1 October 2020 and 30 June 2022 at seven hospitals. Treatment, outcome and VWD‐related HCRU data associated with the prevention/treatment of surgery‐related bleeds were collected at first (index) event, for 12 months pre‐index and 3–12 months post‐index. Results Twenty patients (55.0% female, 90.0% White/Caucasian, mean age 56.7 years) received rVWF to prevent/treat surgery‐related bleeds at index: normal haemostasis following abnormal bleeding was achieved for all applicable bleeds with limited requirement for additional treatments. Only four patients (all VWD type 2) received exogenous factor VIII in addition to rVWF at index. There were no treatment switches and no likely treatment‐related complications. Physician‐rated treatment satisfaction was ‘excellent’ (36.7%) or ‘good’ (63.3%) for all rVWF‐treated surgery‐related bleeds ( n = 30). Conclusions Results support the effectiveness and safety profile of rVWF in a surgical setting in adults with VWD, supplementing the growing body of evidence for rVWF.